共 50 条
- [42] Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic AdenocarcinomaONCOLOGIST, 2021, 26 (10): : 825 - e1674George, Thomas J.Ali, AzkaWang, YuLee, Ji-HyunIvey, Alison M.DeRemer, DavidDaily, Karen C.Allegra, Carmen J.Hughes, Steven J.Fan, Z. HughCameron, Miles E.Judge, Andrew R.Trevino, Jose G.
- [43] A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in BelgiumTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15Verbruggen, LiseVerheggen, LisaVanhoutte, GreetjeLoly, CatherineLybaert, WillemBorbath, IvanVergauwe, PhilippeHendrickx, KoenDebeuckelaere, Celinede Haar-Holleman, AmyVan Laethem, Jean-LucPeeters, Marc
- [44] Impact of first-line fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with advanced gastroesophageal adenocarcinoma: A retrospective analysisJOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)Lino, Aline Da RochaMoreira, Raphael BrandaoGomes, Jessica RibeiroSoares de Sousa, Tarcia TarcianeAbrahao, Carina MinaMartins Junior, Rodnei MerlrinaAlessandretti, Matheus BongersFernandes Amarante, Marcus PauloBarros Schutz, Fabio AugustoKawamura, CarolinaSchmerling, RafaelCruz, Marcelo RochaMaluf, Fernando C.Buzaid, Antonio C.Peixoto, Renata D'Alpino
- [45] A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in BelgiumTHERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15Verbruggen, LiseVerheggen, LisaVanhoutte, GreetjeLoly, CatherineLybaert, WillemBorbath, IvanVergauwe, PhilippeHendrickx, KoenDebeuckelaere, Celinede Haar-Holleman, AmyVan Laethem, Jean-LucPeeters, Marc
- [46] A phase II study of irinotecan, oxaliplatin, 5-fluorouracil, leucovorin (FOLFOXIRI) as a first-line chemotherapy in metastatic gastric cancer.JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 197S - 197SLee, J.Kang, W.Lee, S.Kwon, J.Kim, H.Lee, H.Lim, H.Park, J.Park, Y.Park, K.
- [47] Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancerJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Kopetz, S.Glover, K. Y.Eng, C.Wolff, R. A.Chang, D. Z.Adinin, R. B.Morris, J.Abbruzzese, J. L.Hoff, P. M.
- [48] Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S-1 as second-line chemotherapy in metastatic pancreatic cancerJGH OPEN, 2021, 5 (06): : 679 - 685Ikezawa, KenjiKiyota, RyosukeTakada, RyojiDaiku, KazumaMaeda, ShingoImai, ToshihiroAbe, YutaroKai, YugoYamai, TakuoFukutake, NobuyasuNakabori, TasukuAshida, ReikoUehara, HiroyukiTabuchi, TakahiroKatayama, KazuhiroOhkawa, Kazuyoshi
- [49] First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly scheduleANNALS OF ONCOLOGY, 2004, 15 (12) : 1766 - 1772Masi, GAllegrini, GCupini, SMarcucci, LCerri, EBrunetti, IFontana, ERicci, SAndreuccetti, MFalcone, A
- [50] BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FROM A US PAYER PERSPECTIVEVALUE IN HEALTH, 2015, 18 (03) : A196 - A196Bui, C. N.O'Day, K.Flanders, S.Oestreicher, N.Francis, P.Posta, L.Popelar, B.Tang, H.Balk, M.